Drug Approval | May 25, 2026
Datroway wins US nod in aggressive breast cancer subtype
Clearance marks major shift beyond chemotherapy
Clearance marks major shift beyond chemotherapy
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
